NeurogesX and Astellas Enter Commercialization Agreement for Q...(eurogesX' product candidates may have un...),Health

Date:6/22/2009

eurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; Astellas may not devote sufficient resources or personnel to the commercialization of Qutenza; adoption of Qutenza by physicians may be longer than anticipated; discussions with governmental or administrative entities may not result in adequate reimbursement or pricing to support commercialization efforts for Qutenza; Astellas may not elect to make option related payments or co-develop NGX-1998; positive results in Qutenza clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; and other difficulties or delays in the successful commercialization of Qutenza, carrying out activities or obtaining payments under the Agreement and in clinical development of, and obtaining regulatory approval for, NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                   The Ruth Group
    Stephen Ghiglieri                 Sara Pellegrino (investors)
    Chief Financial Officer           (646) 536-7002
    (650) 358-3310                    spellegrino@theruthgroup.com

    Astellas Pharma Europe            Jason Rando (media)/Janine McCargo
    Mindy Dooa                        (646) 536-7025/7033
    Corporate Communications Director jrando@theruthgroup.com
    +44 (0)7826 912 339               jmccargo@theruthgroup.com
    mindy.dooa@eu.astellas.com

'/>"/>

SOURCE NeurogesX, Inc.; Astellas Pharma Europe Ltd. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. NeurogesX Reports Fourth Quarter and Year-End 2008 Results
2. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
3. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
4. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
5. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
6. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
7. Astellas Names Head of Global R&D Operations
8. Astellas Adds CNS Therapy Area Leader to Global R&D Team
9. Astellas Hires New Vice President of Compliance
10. Astellas Announces New Vice President of Marketing
11. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia